文献速递眼底病与葡萄膜炎

全视网膜光凝或雷珠单抗治疗增殖性糖尿病视网膜病变5年视野变化

Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy.
PubMed 文献 · JAMA Ophthalmol · 2020-01-01

本研究为Protocol S随机临床试验的辅助研究事后分析,纳入增殖性糖尿病视网膜病变眼,比较全视网膜光凝(PRP)与玻璃体腔注射0.5 mg雷珠单抗治疗5年内视野总点分变化。结果显示PRP组视野损害大于雷珠单抗组,且激光治疗与视野点分下降相关,而雷珠单抗注射次数无关联。

要点

  • 纵向回归中初始PRP与平均点分下降208 dB相关,额外PRP为77 dB,眼内激光为325 dB。
  • 雷珠单抗注射次数与视野点分变化无关联(每针-9,95%CI -22至3)。

核心结论

  • Protocol S有限数据提示,除PRP外还有其他因素与增殖性糖尿病视网膜病变治疗眼的视野丧失相关。

研究设计与样本

  • 多中心(美国55个中心)随机临床试验的事后辅助研究分析,纳入Protocol S中增殖性糖尿病视网膜病变眼,数据收集于2012年2月至2018年2月。

主要发现

  • 对雷珠单抗组PRP后视野结果进行删失后,5年总点分平均变化为-201(442)dB。
  • 纵向回归分析中,初始PRP与平均点分下降208(95%CI 112-304)dB相关,额外PRP与77(95%CI 21-132)dB相关,眼内激光与325(95%CI 211-439)dB相关。
  • 过去一年雷珠单抗注射次数与点分变化无关联(每针-9,95%CI -22至3)。

临床怎么用

  • 在选择PRP或雷珠单抗治疗增殖性糖尿病视网膜病变时,需考虑PRP与长期视野损害相关,但视野丧失也可能涉及其他因素。

局限性

  • 5年时仅79只眼(33.8%)有视野结果可用,数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Preservation of peripheral visual field (VF) is considered an advantage for anti-vascular endothelial growth factor agents compared with panretinal photocoagulation (PRP) for treatment of proliferative diabetic retinopathy. Long-term data on VF are important when considering either treatment approach. OBJECTIVE: To further evaluate changes in VF throughout 5 years among eyes enrolled in the Protocol S clinical trial, conducted by the DRCR Retina Network. DESIGN, SETTING, AND PARTICIPANTS: Post hoc analyses of an ancillary study within a multicenter (55 US sites) randomized clinical trial. Individuals with eyes with proliferative diabetic retinopathy enrolled in Protocol S were included. Data were collected from February 2012 to February 2018. Analysis began in June 2018. INTERVENTIONS: Panretinal photocoagulation or intravitreous injections of 0.5-mg ranibizumab. Diabetic macular edema, whenever present, was treated with ranibizumab in both groups. Panretinal photocoagulation could be administered to eyes in the ranibizumab group when failure or futility criteria were met. MAIN OUTCOMES AND MEASURES: Mean change in total point score on VF testing with the Humphrey Field Analyzer 30-2 and 60-4 test patterns. RESULTS: Of 394 eyes enrolled in Protocol S, 234 (59.4%) were targeted for this ancillary study. Of these, 167 (71.4%) had VF meeting acceptable quality criteria at baseline (median [interquartile range] age, 50 [43-58] years; 90 men [53.9%]). At 5 years, 79 (33.8%) had results available. The mean (SD) change in total point score in the PRP and ranibizumab groups was -305 (521) dB and -36 (486) dB at 1 year, respectively, increasing to -527 (635) dB and -330 (645) dB at 5 years, respectively (P = .04). After censoring VF results after PRP treatments in the ranibizumab group, the 5-year mean change in total point score was -201 (442) dB. In a longitudinal regression analysis of change in total point score including both treatment groups, laser treatment was associated with a mean point decrease of 208 (95% CI, 112-304) dB for the initial PRP session, 77 (95% CI, 21-132) dB for additional PRP sessions, and 325 (95% CI, 211-439) dB for endolaser. No association was found between change in point score and the number of ranibizumab injections during the previous year (-9 per injection [95% CI, -22 to 3]). CONCLUSIONS AND RELEVANCE: The limited data available from Protocol S suggest that there are factors besides PRP associated with VF loss in eyes treated for proliferative diabetic retinopathy. Further clinical research is warranted to clarify the finding. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01489189.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Maguire MG, Liu D, Glassman AR, et al. Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy. JAMA Ophthalmol. 2020. PMID: 31999300. doi:10.1001/jamaophthalmol.2019.5939

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。